| Journal | Brain, behavior, and immunity |
| Study Type | Randomized Trial |
| Population | Human participants |
This systematic review and meta-analysis addresses a critical gap in understanding cannabis’s inflammatory effects across healthy and psychiatric populations. With cannabis use rising for both medical and recreational purposes, clinicians need evidence-based guidance on how cannabinoids affect systemic inflammation.
This comprehensive meta-analysis of 46 studies involving 54,382 participants examined peripheral inflammatory biomarkers in cannabinoid users versus non-users. The analysis included 190 effect sizes from observational studies, prospective studies, and randomized controlled trials. Observational data suggested cannabis use was associated with higher levels of anti-inflammatory markers, though the clinical significance and causality remain unclear given the heterogeneous study designs and populations included.
“While intriguing, this meta-analysis highlights how much we still don’t understand about cannabis and inflammation. The mixed findings across study types reinforce that we cannot yet make definitive claims about cannabinoids’ anti-inflammatory effects in clinical practice.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does regular cannabis use lower inflammation in the body?
The evidence is unclear. In this meta-analysis, observational data suggested that cannabis use was associated with higher levels of anti-inflammatory markers. However, the clinical significance of this finding and whether cannabis actually causes these changes remain unclear, given the mixed study designs and populations included.
How many studies were included in this cannabis inflammation meta-analysis?
The analysis pooled 46 studies involving 54,382 participants and was published in Brain, Behavior, and Immunity. It included 190 effect sizes drawn from observational studies, prospective studies and randomized controlled trials, comparing peripheral inflammatory biomarkers in cannabinoid users with those in non-users.
Which groups of people did this inflammation review look at?
The review examined cannabis’s inflammatory effects across both healthy and psychiatric populations. It addressed a gap in understanding how cannabinoids affect systemic inflammation at a time when cannabis use is rising for both medical and recreational purposes.
Should cannabis be used to treat inflammatory conditions based on this study?
Not on this evidence alone. Although some biomarker associations were found, there is not yet sufficient clinical evidence to establish a therapeutic benefit or optimal dosing for cannabis in inflammatory conditions. The findings are best interpreted cautiously rather than as a reason to use cannabis solely for anti-inflammatory purposes.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
